Medical Care Technologies (OTC PINK:MDCE) Advances AI Research to Help Identify Early Health Risks in Skin Cancer, Vision, Wound Care, and Mental Wellness

Rhea-AI Summary

Medical Care Technologies (OTC PINK:MDCE) on October 9, 2025 highlighted progress in its AI preventive health platform across four verticals: skin health, ocular health, wound monitoring, and mental & behavioral health. The company tied each module to global burden statistics: 60,000+ annual deaths from melanoma and other skin cancers, 100M+ people with vision loss risk from diabetic/vascular eye disease, 5M+ chronic wound/post-surgical infection cases annually, and 700,000+ annual suicide deaths. The release described AI-assisted imaging for earlier detection and a non-clinical emotion-tracking tool for self-monitoring, and reiterated forward-looking risks to development, regulatory and operational outcomes.

CEO emphasized that AI is intended to help reveal early signs but not replace clinicians.

MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial intelligence-powered preventive health technology, today emphasized the urgent human need driving each vertical of its AI platform - underscoring the global lives lost and affected every year to conditions that may be better managed through earlier detection and awareness.

Skin Health

Over 60,000 people die from melanoma and other skin cancers each year. Many are diagnosed too late. MDCE's dermatology module is designed to help users identify visible irregularities earlier through AI-assisted imaging.

Ocular Health

More than 100 million people worldwide experience vision loss from diabetic and vascular eye diseases. MDCE's ocular imaging system aims to analyze retinal patterns that may signal early changes before irreversible damage occurs.

Wound Monitoring

Over 5 million chronic wound and post-surgical infection cases occur annually, often leading to preventable complications. MDCE's wound module seeks to enable continuous image-based tracking for improved recovery oversight.

Mental & Behavioral Health

More than 700,000 lives are lost to suicide every year. MDCE's non-clinical, AI-assisted mental health tracker uses facial micro-expression and emotion-recognition models to explore patterns tied to stress, fatigue, and emotional decline - supporting greater awareness and self-monitoring.

"These global health statistics remind us why early detection and awareness matter," said CEO Marshall Perkins III. "AI cannot replace doctors, but it can help reveal the unseen - and that visibility can make all the difference."

Safe Harbor Statement

This press release contains forward-looking statements based on current expectations regarding future research, technology development, and business outcomes. Such statements are subject to risks and uncertainties that may cause actual results to differ materially, including technical performance, regulatory changes, and operational challenges. Medical Care Technologies Inc. assumes no obligation to update or revise forward-looking statements except as required by law.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC Pink: MDCE) develops AI-based imaging and biometric technologies to promote early health awareness across dermatology, ocular, wound care, and behavioral health. The company is committed to ethical innovation, data transparency, and responsible AI development.

Visit www.medicalcaretechnologies.com for more information.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (MDCE) announce on October 9, 2025?

MDCE said it is advancing its AI preventive health platform across skin, ocular, wound, and mental health modules to help detect early signs through imaging and emotion analysis.

How does MDCE's dermatology module aim to help detect skin cancer earlier?

The dermatology module uses AI-assisted imaging to identify visible irregularities earlier, referencing over 60,000 annual deaths from melanoma and related cancers.

What is MDCE's ocular health solution designed to detect for investors following the Oct 9, 2025 announcement?

MDCE's ocular imaging system aims to analyze retinal patterns that may signal early changes tied to diabetic and vascular eye disease affecting over 100 million people.

What capability did MDCE describe for wound monitoring in the October 9, 2025 release?

MDCE described a wound module for continuous image-based tracking to improve recovery oversight amid over 5 million chronic wound and post-surgical infection cases annually.

What did MDCE say about its mental and behavioral health tool on October 9, 2025?

The company described a non-clinical, AI-assisted mental health tracker using facial micro-expression and emotion-recognition models for self-monitoring and awareness.

Does the October 9, 2025 release include any regulatory approvals or financial guidance for MDCE?

No. The release discusses research and platform development and includes a safe-harbor note about forward-looking risks; it does not announce approvals or financial guidance.